PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts.

The artificial-intelligence lending platform expects first-quarter revenue of about $200 million, better than estimates of $184.6 million.

Income should pour into your account, not dribble in. We take a three-legged approach to mREIT investing for income. Today, we dive into the third leg.

Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments

NORTH CHICAGO, Ill. and WALTHAM, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio's proprietary technology.

Meta Platforms (NASDAQ: META) has extended its historic rally, closing higher for the 17th consecutive session and marking its longest winning streak ever. The stock has surged 18% during this run and is now up 22% year-to-date, closing at $719.80 on February 11.

TruBridge (TBRG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Oil futures fell Wednesday, threatening to end a three-day winning streak, after industry data showed a large rise in U.S. crude inventories.

Retail investors can really benefit from following the recent developments coming out of Wall Street, especially during volatile market times like these, which President Trump's recent trade tariffs have sparked. In all the uncertainty about what might happen to the United States economy, markets have lost track of what's essential.

I once thought holding cash for a market crash was smart, but waiting for crashes is a risky game. Inflation devalues cash much faster than investing. Market timing is tough. Predicting corrections consistently is nearly impossible, and staying invested can prevent the damage inflation causes to your purchasing power. Instead of waiting for the "perfect" moment, I focus on consistent investing in resilient infrastructure and public real estate that outperforms the market.

VANCOUVER, BC / ACCESS Newswire / February 12, 2025 / Alset AI Ventures Inc.(TSXV:GPUS)(OTC:ALSCF)(FSE:1R60, WKN:A3ESVQ)("Alset AI" or the "Company") an artificial intelligence (AI) venture company advancing innovation through strategic investment and cloud computing solutions, announces the appointment of Jaret Christopher as a strategic advisor. Mr. Christopher brings a wealth of entrepreneurial experience in particular in the technology sector, and will provide strategic advisory and business development services to enhance the Company's AI ecosystem.

Growth Investor Pro's Alex King shares why hedging is crucial in volatile markets; using QQQ and PSQ ETFs to protect your portfolio. Mastering a charting method like Elliott Waves and Fibonacci is essential for recognizing patterns and predicting price movements.

Company to host a webcast t oday at 8:30 a.m. Eastern Time

Experience the W56 208” extended wheelbase step van at the Work Truck Week Ride & Drive, showcasing its road-tested durability.

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs. placebo Achieved statistical significance on key secondary endpoints at Week 12 on ACR20, ACR50 and CDAI LDA Demonstrated highest ever reported responses on key secondary endpoints at Week 14 on ACR20, ACR50, ACR70 and CDAI LDA 69% of rosnilimab-treated patients achieved CDAI LDA at Week 14 and appear to show sustained CDAI LDA and ACR50 responses and potentially deepening ACR70 responses out to Week 28 Robust pharmacological activity observed in reduction of PD-1high T cells, increase in total Tregs …

Yesterday's announcement about including Firefly Neuroscience in the Nvidia Connect program further broadens Nvidia's extensive ecosystem and enhances its growth potential in the $10 trillion healthcare market. Nvidia's robust R&D spending and strong balance sheet ensure it stays way ahead of the main competitor, AMD, which is struggling with inventory and uncertain AI revenue growth prospects. AI tailwinds, including major projects like OpenAI's Stargate and positive news from Europe, reinforce Nvidia's growth prospects.

Generated Record Quarterly Revenue of $85 Million, a 35% Annual Increase Generated Record Quarterly Revenue of $85 Million, a 35% Annual Increase

NEW YORK, NY / ACCESS Newswire / February 12, 2025 / If you suffered a loss on your Innovative Industrial Properties, Inc. (NYSE:IIPR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/innovative-industrial-properties-inc-lawsuit-submission-form?prid=128899&wire=1 or contact Joseph E. Levi, Esq.

CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP).

Collaboration will combine AbbVie's oncology expertise and Xilio's proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers Xilio to host investor conference call and webcast today at 8:30 am EST NORTH CHICAGO, Ill. and WALTHAM, Mass.